Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

22% and 24% of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group...

Related Keywords

United States ,Americans ,Sarah Oconnell ,Andrew Cheng ,Pa Fibroscan ,Stephen Harrison ,Austin Murtagh ,Linkedin ,Nasdaq ,Akero Therapeutics Inc ,Twitter ,Pinnacle Clinical Research ,Exchange Commission ,Liver Biopsy Analysis Set ,Non Invasive Markers ,Change From Baseline ,Full Analysis ,Serum Markers ,Conference Call ,South San ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Markets ,